HDAC9 and metabolic disease: Hence the induction of reversible safe lipid droplet accumulation in the liver by short-term administration of Entinostat or similar Class I HDAC inhibitors, temporarily and rapidly removing toxic free fatty acids from the cells and reducing the load of carbohydrates in the bloodstream that would otherwise interfere with insulin signalling, may provide a window of therapeutic opportunity to allow commencement of longer-term treatment strategies for obesity and metabolic disease such as changes in diet and exercise.